XBiotech Inc. (XBIT) Reaches $10.76 52-Week High; 1 Analysts Are Bullish The Boston Beer Company, Inc. (SAM) Last Week

XBiotech Inc. (NASDAQ:XBIT) Logo

Among 7 analysts covering Boston Beer Co (NYSE:SAM), 1 have Buy rating, 1 Sell and 5 Hold. Therefore 14% are positive. Boston Beer Co had 11 analyst reports since September 14, 2018 according to SRatingsIntel. The firm has “Buy” rating by Guggenheim given on Wednesday, March 6. The stock of The Boston Beer Company, Inc. (NYSE:SAM) earned “Neutral” rating by Macquarie Research on Thursday, February 21. Guggenheim maintained it with “Buy” rating and $308 target in Wednesday, February 20 report. The stock of The Boston Beer Company, Inc. (NYSE:SAM) earned “Hold” rating by BMO Capital Markets on Thursday, February 21. Cowen & Co maintained The Boston Beer Company, Inc. (NYSE:SAM) rating on Friday, February 22. Cowen & Co has “Hold” rating and $311 target. The rating was maintained by Susquehanna on Tuesday, January 8 with “Neutral”. The rating was maintained by Citigroup on Monday, October 29 with “Neutral”. Citigroup maintained The Boston Beer Company, Inc. (NYSE:SAM) rating on Tuesday, February 26. Citigroup has “Hold” rating and $311 target. See The Boston Beer Company, Inc. (NYSE:SAM) latest ratings:

06/03/2019 Broker: Guggenheim Rating: Buy New Target: $335 Maintain
26/02/2019 Broker: Citigroup Rating: Hold New Target: $311 Maintain
22/02/2019 Broker: Cowen & Co Rating: Hold New Target: $311 Maintain
21/02/2019 Broker: Jefferies Rating: Hold Maintain
21/02/2019 Broker: BMO Capital Markets Rating: Hold New Target: $275 Maintain
21/02/2019 Broker: Macquarie Research Old Rating: Underperform New Rating: Neutral Old Target: $260 New Target: $275 Upgrade
20/02/2019 Broker: Guggenheim Rating: Buy New Target: $308 Maintain
08/01/2019 Broker: Susquehanna Old Rating: Neutral New Rating: Neutral Old Target: $283 New Target: $241 Maintain
13/12/2018 Broker: UBS Rating: Sell New Target: $228 Initiates Coverage On
29/10/2018 Broker: Citigroup Old Rating: Neutral New Rating: Neutral Old Target: $285 New Target: $290 Maintain

The stock of XBiotech Inc. (NASDAQ:XBIT) hit a new 52-week high and has $11.19 target or 4.00% above today’s $10.76 share price. The 8 months bullish chart indicates low risk for the $385.42M company. The 1-year high was reported on Mar, 10 by Barchart.com. If the $11.19 price target is reached, the company will be worth $15.42M more. The stock increased 7.17% or $0.72 during the last trading session, reaching $10.76. About 285,898 shares traded or 70.38% up from the average. XBiotech Inc. (NASDAQ:XBIT) has risen 90.53% since March 10, 2018 and is uptrending. It has outperformed by 86.16% the S&P500. Some Historical XBIT News: 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY

More important recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Seekingalpha.com which released: “XBiotech up 4% premarket on positive bermekimab data – Seeking Alpha” on March 05, 2019, also Seekingalpha.com published article titled: “XBiotech up 13% on positive bermekimab data – Seeking Alpha”, Globenewswire.com published: “Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting – GlobeNewswire” on March 01, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) was released by: Seekingalpha.com and their article: “Key events next week – healthcare – Seeking Alpha” with publication date: February 22, 2019.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $385.42 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

The stock increased 0.54% or $1.68 during the last trading session, reaching $314.08. About 100,518 shares traded. The Boston Beer Company, Inc. (NYSE:SAM) has risen 87.00% since March 10, 2018 and is uptrending. It has outperformed by 82.63% the S&P500. Some Historical SAM News: 16/04/2018 – BOSTON BEER COMPANY INC SAM.N : GOLDMAN SACHS RAISES TO NEUTRAL FROM SELL; 25/04/2018 – BOSTON BEER COMPANY INC – 2018 ESTIMATED CAPITAL SPENDING OF BETWEEN $55 MLN AND $65 MLN; 25/04/2018 – Boston Beer Sees FY EPS $6.30-EPS $7.30; 20/03/2018 Boston Beer Closes Above 50-Day Moving Average: Technicals; 25/04/2018 – BOSTON BEER 1Q NET REV. $190.5M, EST. $176.0M; 26/04/2018 – BOSTON BEER COMPANY INC SAM.N : RBC RAISES TARGET PRICE TO $175 FROM $162; 18/04/2018 – Boston Beer Earnings: Things Are Looking ‘Rosé’ — Barrons.com; 30/03/2018 – BOSTON BEER COMPANY – ON MARCH 27, ENTERED AGREEMENT TO AMEND CO’S EXISTING $150 MLN REVOLVING LINE OF CREDIT AGREEMENT – SEC FILING; 30/03/2018 – BOSTON BEER COMPANY – AMENDMENT EXTENDS MATURITY DATE OF CREDIT FACILITY UNDER LINE OF CREDIT AGREEMENT FROM MARCH 31, 2019 TO MARCH 31, 2023; 25/04/2018 – Boston Beer Tops Estimates as New CEO Takes Over — Earnings Review

More notable recent The Boston Beer Company, Inc. (NYSE:SAM) news were published by: Benzinga.com which released: “50 Stocks Moving In Thursday’s Mid-Day Session – Benzinga” on February 21, 2019, also Investorplace.com with their article: “5 Must-See Stock Charts for Friday: Newmont, Nike, Tesla – Investorplace.com” published on February 21, 2019, Investorplace.com published: “3 Big Stock Charts for Friday: Equifax, Mattel and Kimberly Clark – Investorplace.com” on February 22, 2019. More interesting news about The Boston Beer Company, Inc. (NYSE:SAM) were released by: Fool.com and their article: “Wall Street Takes a Slice Out of the Pizza, Pops Open a Craft Beer – Motley Fool” published on February 25, 2019 as well as Bizjournals.com‘s news article titled: “Sam’s Club has plans to test new tech at its cashierless store – Dallas Business Journal” with publication date: March 04, 2019.

The Boston Beer Company, Inc. produces and sells alcohol beverages primarily in the United States. The company has market cap of $3.61 billion. The Company’s flagship beer is Samuel Adams Boston Lager. It has a 40.15 P/E ratio. The firm sells approximately 60 beers under the Samuel Adams and the Sam Adams brands; 20 hard cider beverages under the Angry Orchard brand; 13 flavored malt beverages under the Twisted Tea brand; and 4 hard seltzer beverages under the Truly Spiked & Sparkling brand name, as well as approximately 40 beers under A&S Brewing trade name.

Investors sentiment increased to 0.95 in Q4 2018. Its up 0.05, from 0.9 in 2018Q3. It increased, as 22 investors sold The Boston Beer Company, Inc. shares while 81 reduced holdings. 38 funds opened positions while 60 raised stakes. 9.14 million shares or 9.94% more from 8.31 million shares in 2018Q3 were reported. Kbc Nv owns 5,228 shares. Amer Century Companies owns 5,648 shares for 0% of their portfolio. 10,124 were reported by First Tru Advisors L P. Contravisory Invest Mgmt has invested 0.08% in The Boston Beer Company, Inc. (NYSE:SAM). Moreover, Maplelane Capital Ltd Liability Company has 0.08% invested in The Boston Beer Company, Inc. (NYSE:SAM). Commonwealth Of Pennsylvania School Empls Retrmt stated it has 1,509 shares or 0.01% of all its holdings. Kornitzer Mgmt Ks owns 8,240 shares. 781 were reported by Hanseatic Mgmt Incorporated. Principal Fin Grp Inc Inc stated it has 0.01% in The Boston Beer Company, Inc. (NYSE:SAM). Oakworth Cap Inc, Alabama-based fund reported 500 shares. Utd Automobile Association holds 1,326 shares. 35,577 were accumulated by Btim. Guggenheim Capital Ltd Liability holds 2,666 shares. Wells Fargo And Mn reported 33,718 shares. Moreover, Ellington Gru Ltd Limited Liability Company has 0.18% invested in The Boston Beer Company, Inc. (NYSE:SAM) for 2,500 shares.

The Boston Beer Company, Inc. (NYSE:SAM) Institutional Positions Chart


Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *